I don't know how long it extends survival for - they will announce that at an upcoming conference.
This is being called "triplet therapy" = (1) a second generation hormonal + (2) ADT (e.g. Lupron) +(3) Chemo (e.g., Taxotere/docetaxel)
The other second-generation hormonal therapy that recently was found to extend survival as part of a triplet was abiraterone (Zytiga) in the PEACE1 trial:
Thanks for highlighting this Allen. Would think the insights applies to those who are micrometastic / BCR?
As someone BCR after primary therapy (but still low PSA), I'm trying to decide what to do and when.
The "triplet" seems to provide the best outcomes for the group studied, butI presume chemo was generally added given distant / multiple metastases. The adverse reactions and side effects seem notable too.
Idk if it applies to those whose metastases only show up on PET scans or if they are recurrent - it does only apply to those who have not been on medication, although temporary adjuvant ADT is probably OK - but I'm just guessing.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.